Skip to Content

Guanabenz Disease Interactions

There are 5 disease interactions with guanabenz:

Moderate

Alpha-2 Agonists (Central) (Includes Guanabenz) ↔ Bradyarrhythmia

Moderate Potential Hazard, High plausibility

Applies to: Heart Block, Sinus Node Dysfunction

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.

References

  1. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  2. van Zwieten PA, Thoolen MJ, Timmermans PB "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine." Hypertension 6 (1984): 28-33
  3. "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. Golusinski LL, Blount BW "Clonidine-induced bradycardia." J Fam Pract 41 (1995): 399-401
  5. Schwartz E, Friedman E, Mouallem M, Farfel Z "Sinus arrest associated with clonidine therapy." Clin Cardiol 11 (1988): 53-4
  6. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  7. Byrd BF, Collins HW, Primm RK "Risk factors for severe bradycardia during oral clonidine therapy for hypertension." Arch Intern Med 148 (1988): 729-33
View all 7 references
Moderate

Alpha-2 Agonists (Central) (Includes Guanabenz) ↔ Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression

Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.

References

  1. Kostis JB, Rosen RC, Holzer BC, et al "CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males." Psychopharmacology (Berl) 102 (1990): 163-70
  2. Prasad A, Shotliff K "Depression and chronic clonidine therapy." Postgrad Med J 69 (1993): 327-8
  3. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  4. "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  5. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
View all 5 references
Moderate

Alpha-2 Agonists (Central) (Includes Guanabenz) ↔ Hypotension

Moderate Potential Hazard, High plausibility

Applies to: Hypotension, Cerebrovascular Insufficiency, Ischemic Heart Disease, Peripheral Arterial Disease

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

References

  1. Greene CS, Gretler DD, Cervenka K, et al "Cerebral blood flow during the acute therapy of severe hypertension with oral clonidine." Am J Emerg Med 8 (1990): 293-6
  2. Fruncillo RJ, Gibbons WJ, Vlasses PH, Ferguson RK "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274
  3. Bauer JH "Effects of guanabenz therapy on renal function and body fluid composition." Arch Intern Med 143 (1983): 1163-7
  4. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  5. "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  6. Anavekar SN, Jarrott B, Toscano M, Louis WJ "Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects." Eur J Clin Pharmacol 23 (1982): 1-5
  7. Mosley C, O'Connor DT, Taylor A, et al "Comparative effects of antihypertensive therapy with guanabenz and propranolol on renal vascular resistance and left ventricular mass." J Cardiovasc Pharmacol 6 (1984): s757-61
  8. Dziedzic SW, Elijovich F, Felton K, et al "Effect of guanabenz on blood pressure responses to posture and exercise." Clin Pharmacol Ther 33 (1983): 151-5
  9. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  10. Given BD, Taylor T, Lilly LS, Dzau VJ "Symptomatic hypotension following the clonidine suppression test for pheochromocytoma." Arch Intern Med 143 (1983): 2195-6
  11. van Zwieten PA, Thoolen MJ, Timmermans PB "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine." Hypertension 6 (1984): 28-33
  12. Bosanac P, Dubb J, Walker B, et al "Renal effects of guanabenz: a new antihypertensive." J Clin Pharmacol Nov-Dec (1976): 631-6
View all 12 references
Moderate

Guanabenz (Includes Guanabenz) ↔ Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease

Guanabenz is primarily metabolized by the liver. Pharmacokinetic data indicate that the plasma clearance of guanabenz is significantly reduced and its elimination half-life significantly prolonged in patients with liver disease. Therapy with guanabenz should be administered cautiously in patients with impaired hepatic function. Careful monitoring of blood pressure during dosage titration is recommended.

References

  1. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. Lasseter KC, Shapse D, Pascucci VL, Chiang ST "Pharmacokinetics of guanabenz in patients with impaired liver function." J Cardiovasc Pharmacol 6 (1984): s766-70
Moderate

Guanabenz (Includes Guanabenz) ↔ Renal Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The disposition of orally administered guanabenz is altered modestly in renal impairment. The manufacturer states that the plasma clearance of guanabenz is reduced and its half-life prolonged in patients with impaired renal function, and more so in those on hemodialysis. The clinical significance of these findings is unknown. Careful monitoring of blood pressure during dosage titration is recommended.

References

  1. Dubrow A, Mittman N, DeCola P, et al "Safety and efficacy of guanabenz in hypertensive patients with moderate renal insufficiency." J Clin Hypertens 1 (1985): 322-5
  2. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

guanabenz drug Interactions

There are 321 drug interactions with guanabenz

guanabenz alcohol/food Interactions

There is 1 alcohol/food interaction with guanabenz

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide